Suscribirse

Elective Melody valve insertion in mitral position: What have we learnt from our first and successful case? - 14/08/21

Doi : 10.1016/j.acvdsp.2021.06.089 
Virginie Fouilloux  : auteur, Philippe Aldebert : co-auteur, Marien Lenoir : co-auteur, Fedoua El Louali : co-auteur, Célia Gran : co-auteur, Caroline Ovaert
 Service medico-chirurgical des cardiopathies congénitales, hôpital d’enfants de la Timone, 13385 Marseille, France 

Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Resumen

Introduction

Melody valve insertion in mitral position is no longer an experimental procedure and is now an acceptable option for severe mitral valve disease in infants and neonates.

Although there are more and more publications outlining the outcome, our first and successful case taught us a couple of points that we would like to share.

Case report

A 20 days-old baby with severe congenital mitral insufficiency underwent Melody valve implantation. The stent was fashioned to avoid left ventricular outflow tract obstruction and expanded with a 14mm balloon. A small ASD was created to allow further percutaneous balloon dilation. The baby was discharged after 6weeks and treated with antiplatelet therapy. Postoperative management consisted in close transthoracic echocardiographic follow-up. Two percutaneous balloon dilatations of the stent (14 and 16mm) were performed, respectively 9 and 16months after the initial surgery.

The patient presented infective endocarditis (Haemophilus influenzae) 26months after surgery. TTE showed moderate Melody valve regurgitation and stenosis (mean gradient: 11mmHg) with post-capillary pulmonary hypertension. Mitral valve replacement was performed after 6weeks of antibiotic therapy. The stent was explanted and a 19mm mechanical prosthetic valve was inserted.

Postoperative course was uneventful.

Discussion

Melody valve in mitral position is now an accepted option but morbidity and mortality remain significant. Post-implantation management is challenging and guidelines are missing.

Percutaneous stent dilation, hybrid valve in valve implantation and mechanical mitral valve replacement are 3 possible options in case of valve dysfunction.

The per-operative pictures (Fig. 1, Fig. 2) help to understand why, in our case, the first 2 options would have failed.

Fig. 1 shows non-calcified and mobile leaflets. One leaflet had a small 2mm perforation. The stent itself, in contrast, was so thickened that dilatation or valve in valve procedure would have failed at this stage.

Conclusion

Major endothelialization of the stent might significantly limit post-implantation management options.

We believe that heart teams have to be aware of this potential evolution of the stent in order to establish the best procedural strategy in these patients.

El texto completo de este artículo está disponible en PDF.

Keywords : Congenital heart disease, Mitral valve replacement, Melody valve


Esquema


© 2021  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 13 - N° 4

P. 327 - septembre 2021 Regresar al número
Artículo precedente Artículo precedente
  • Impact of genotype on the progression of aortic disease in patients with Marfan syndrome and Loeys–Dietz syndrome
  • Rémi Vincent, Fernanda Bajanca, Thomas Edouard, Julie Plaisancie, Marion Aubert-Mucca, Bertrand Chesneau, Aitor Guitarte Vidaurre, Yves Dulac
| Artículo siguiente Artículo siguiente
  • Relationship between right ventricle remodeling index and outcomes in patients with pulmonary arterial hypertension and pre-tricuspid shunts
  • Maëlle Selegny, Emmanuelle Fournier, Marion Audié, Isabelle Van Aerschot, Meriem Mostefa-Kara, Sarah Cohen, Lisa Guirgis, Claire Foray, Clément Batteux, Régine Roussin, Joy Zoghbi, Emre Belli, Xavier Jaïs, Olivier Sitbon, Laurent Savale, David Montani, Marc Humbert, Sébastien Hascoet

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.